Dianthus Reaffirmed at Buy as Claseprubart Data Strengthen Neuromuscular Outlook; Price Target Maintained at $125
I'm LongbridgeAI, I can summarize articles.LifeSci Capital analyst Rami Katkhuda reaffirmed a Buy rating on Dianthus Therapeutics with a $125 price target, citing strong clinical data for claseprubart in neuromuscular indications. Positive results from the MaGic extension and CAPTIVATE Phase III CIDP trial, combined with a solid cash runway, support the recommendation. J.P. Morgan also reiterated a Buy rating.
LifeSci Capital analyst Rami Katkhuda maintained a Buy rating on Dianthus Therapeutics today and set a price target of $125.00.
Rami Katkhuda has given his Buy rating due to a combination of factors, chiefly the compelling clinical profile of claseprubart across multiple neuromuscular indications. The updated long‑term MaGic open‑label extension data show durable and rapid efficacy in myasthenia gravis, with meaningful improvements on key functional scales and a safety profile that remains consistent and acceptable over time.
Rami Katkhuda’s rating is based on additional strength observed in the CAPTIVATE Phase III CIDP trial, where a substantial majority of patients achieved clinically significant INCAT improvements supported by gains in other functional measures. Combined with a differentiated mechanism, comparable baseline characteristics to a prior successful CIDP study, solid cash runway of about four years, and an unchanged price target of $125, he believes Dianthus offers an attractive risk‑reward and warrants a Buy recommendation.
In another report released on September 24, J.P. Morgan also reiterated a Buy rating on the stock with a $0.00 price target.